The ARISE-HF trial testing aldose reductase inhibition in asymptomatic diabetic cardiomyopathy did not meet its endpoint but hints at a mechanism that might prevent it.
ATLANTA, GA — A multicenter controlled trial testing the ability of an aldose reductase inhibitor to stabilize early-stage asymptomatic diabetic cardiomyopathy missed its primary endpoint, researchers reported.In the randomized trial, ARISE-HF, the experimental agent called AT-001 did not perform significantly better than placebo on preventing deterioration in peak oxygen uptake , the primary endpoint, but the benefit was significant in a prespecified subgroup, said James L.
Diabetic cardiomyopathy is a heart muscle disease related to chronic hyperglycemia. When the polyol pathway is activated, upregulated aldose reductase prompts release of, a source of osmotic stress and cell death, and release of fructose, which activates neurohormones, reactive oxygen species, and other noxious stimuli leading to myocyte damage, Januzzi explained..
She suggested the signal of benefit in ARISE-HF encourages further evaluation of intervention in advance of diabetic cardiomyopathy if further work can establish that aldose reductase or another strategy prevents rather than treats the underlying pathophysiology. Januzzi reported financial relationships with more than 15 pharmaceutical companies, including Applied Therapeutics, which provided funding for this trial. Lala-Trindade reported financial relationships with AstraZeneca, Cytokinetics, Merck, and Novartis. Vidula reported a financial relationship with Abbott.All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC. This website also contains material copyrighted by 3rd parties.
Diabetic Heart Disease Diabetic Cardiomyopathy Heart Failure Heart CV Risk Cardiovascular Risk CV Risk Factors Cardiovascular Risk Factors Cardiovascular Risk Management Atherosclerotic Heart Disease Atherosclerotic Cardiovascular Disease Coronary Heart Disease Ischemic Heart Disease Coronary Artery Disease Blood Clinical Research Clinical Trials Clinical Studies
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
From Dream to Reality: Low-Cost, Carbon-Neutral Biofuels Are Finally PossibleScience, Space and Technology News 2024
Read more »
AUD/USD plunges to 0.6500 on dismal sentiment, RBA’s neutral interest rate guidanceThe AUD/USD pair faces an intense sell-off as downbeat market sentiment has weakened the appeal of risk-perceived assets.
Read more »
Andy Kim sweeps districts with neutral party leaders in blow to Tammy MurphyAfter weeks of traveling across the Garden State, New Jersey first lady Tammy Murphy and Rep. Andy Kim (D-NJ) can begin to focus on the primary election.
Read more »
Fed Preview: Sentiment will be vulnerable to an outcome that leans neutralUSD gains extend as investors look ahead to the FOMC meeting outcome.
Read more »
Look Inside a Bethesda Colonial With a Neutral Palette and Pops of EggplantThe website that Washington lives by.
Read more »
X’s algorithm should be politically neutralInstead of playing tit for tat, let’s keep our eye on a bigger goal: the rebuilding of a robust culture of free speech.
Read more »